Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amg-548. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 2/20 | 1.00 |
| ▸ | PRKCI | P41743 | 14/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 3/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 1/20 | 1.00 |
| ▸ | CAMK2B | Q13554 | 1/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amg-548 SCHEMBL29395852 | 1.00 | PRKCI (1.00) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| Amg-548 SCHEMBL433425 | 1.00 | PRKCI (1.00) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| Amg-548 SCHEMBL2409009 | 1.00 | PRKCI (1.00) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934599 | 0.89 | PRKCI (0.81) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934604 | 0.89 | PRKCI (0.81) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934602 | 0.89 | PRKCI (0.81) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934628 | 0.89 | MAPK9 (0.82) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934623 | 0.89 | MAPK9 (0.82) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934627 | 0.89 | MAPK9 (0.82) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL4820989 | 0.89 | MAPK9 (0.80) | PRKCIMAPK9MAPK13MAPK14MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | claimed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| EP-3345644-A1 | INHALER | Astrazeneca AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2755708-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-05-09 | — | — | EP | disclosed |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | disclosed |
| EP-2448623-B1 | DISPENSER AND METHOD FOR ENTRAINING POWDER IN AN AIRFLOW | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2341968-B1 | A BREATH ACTIVATED INHALER | ASTRAZENECA AB (SE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2117542-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | AstraZeneca AB (SE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096121-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1937233-A2 | METHODS OF MODULATING INTESTINAL FLUID BALANCE USING CALCIOLYTICS OR CALCIMIMETICS | Amgen Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007027548-A9 | METHODS OF MODULATING INTESTINAL FLUID BALANCE | AMGEN INC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070060625-A1 | Methods of modulating intestinal fluid balance | AMGEN INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2007027548-A2 | METHODS OF MODULATING INTESTINAL FLUID BALANCE | AMGEN INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | MAPK14 361/4885PRKCI 1323/4885MAPK9 491/4885 |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, NFATC1, CD4 | MAPK14 2820/4885PRKCI 1480/4885MAPK9 3133/4885 |
| US-20070060625-A1 | Methods of modulating intestinal fluid balance | SLC10A2, VIP, FABP2 | MAPK14 4049/4885PRKCI 1192/4885MAPK9 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.